Drug Profile
Research programme: anti-soluble E-cadherin antibodies - CadheRx
Latest Information Update: 28 Jul 2019
Price :
$50
*
At a glance
- Originator State University of New York at Stony Brook
- Developer CadheRx; State University of New York at Stony Brook
- Class Antibodies
- Mechanism of Action Apoptosis stimulants; Cadherin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for preclinical development in Solid-tumours(Treatment-resistant) in USA
- 15 Jun 2015 Preclinical trials in Solid tumours (Treatment-resistant) in USA (unspecified route)